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Abstract
Deccox®, containing decoquinate as the active substance, is a feed additive intended to be used for
the prevention of coccidiosis in chickens for fattening at a dose range of 20–40 mg/kg complete feed.
Decoquinate from Deccox® is safe for chickens for fattening at the highest applied concentration in
complete feed of 40 mg/kg. No practically relevant interactions with other additives or veterinary drugs
exist except with bentonite. Decoquinate does not have antibacterial action. Decoquinate is not
genotoxic and not carcinogenic. Deccox® is safe for the consumer under the proposed conditions of
use. No withdrawal period is required to ensure consumer safety. No maximum residue limits are
considered necessary. The inhalation risk for users is considered negligible since inhalation toxicity and
exposure are very low. Deccox® is not an irritant to skin and eyes and has no sensitisation potential.
The ratios predicted environmental concentration/predicted no effect concentration (PEC/PNEC) for
terrestrial, aquatic compartment and sediment are below 1, indicating that decoquinate used in
chickens for fattening up to the highest proposed dose, does not pose a risk for these compartments;
as well, no risk is expected neither for secondary poisoning nor for groundwater contamination. Due to
insufﬁcient evidence, the potential of decoquinate to prevent coccidiosis in chickens for fattening
cannot be established.
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Summary
Following a request from the European Commission, the Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on the safety and
efﬁcacy of Deccox® (decoquinate) for chickens for fattening.
Deccox®, containing decoquinate as the active substance, is a feed additive applied for the
prevention of coccidiosis in chickens for fattening at a dose range of 20–40 mg/kg complete feed.
Based on a tolerance study and supported by a published safety study, the FEEDAP Panel concludes
that decoquinate from Deccox® is safe for chickens for fattening at the highest applied concentration
in complete feed of 40 mg/kg. The margin of safety is between 5 and 10.
No practically relevant interactions with other additives or veterinary drugs exist except with
bentonite. Decoquinate does not have antibacterial action.
Decoquinate is not genotoxic and is not carcinogenic. Deccox® is safe for the consumer under the
proposed conditions of use. No withdrawal period is required to ensure consumer safety. No maximum
residue levels are considered necessary. The inhalation risk for user is considered negligible since
inhalation toxicity and exposure are very low. Deccox® is not an irritant to skin and eyes and has no
sensitisation potential.
The ratios predicted environmental concentration/predicted no effect concentration (PEC/PNEC) for
terrestrial, aquatic compartment and sediment are below 1, indicating that decoquinate used in
chickens for fattening up to the highest proposed dose, does not pose a risk for these compartments;
as well, no risk is expected neither for secondary poisoning nor for groundwater contamination.
Due to insufﬁcient evidence, the potential of decoquinate to prevent coccidiosis in chickens for
fattening cannot be established.
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 10(2) of that Regulation also speciﬁes that for
existing products within the meaning of Article 10(1), an application shall be submitted in accordance
with Article 7, at the latest one year before the expiry date of the authorisation given pursuant to
Directive 70/524/EEC for additives with a limited authorisation period, and within a maximum of seven
years after the entry into force of this Regulation for additives authorised without a time limit or
pursuant to Directive 82/471/EEC.
The European Commission received a request from Pﬁzer Ltd.2 for re-evaluation of the product
Deccox® (decoquinate), when used as a feed additive for chickens for fattening (category:
coccidiostats and histomonostats).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
application to the European Food Safety Authority (EFSA) as an application under Article 10(2) (re-
evaluation of an authorised feed additive). EFSA received directly from the applicant the technical
dossier in support of this application. The particulars and documents in support of the application were
considered valid by EFSA as of 13 September 2013.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, consumer, user and the environment and on the efﬁcacy of the
product Deccox® (decoquinate), when used as a feed additive for chickens for fattening, when used
under the proposed conditions of use (see Section 3.1.5).
1.2. Additional information
The product Deccox® containing 60 g/kg decoquinate as active substance is a feed additive
intended to be used in chickens for fattening for the control of coccidiosis caused by Eimeria spp.
Deccox® was authorised for use in chickens for fattening until July 2014 by Commission Regulation
(EC) No 1289/2004.3 Maximum residue limits (MRLs) and withdrawal time were introduced by
Commission Implementing Regulation (EU) No 291/2014.4
EFSA issued an opinion on the safety and efﬁcacy of Deccox® in accordance with Article 9G of
Council Directive 70/524/EEC (EFSA, 2003).5 In 2013, the EFSA FEEDAP Panel issued an opinion on
the modiﬁcation of the authorisation of Deccox® for chickens for fattening (EFSA FEEDAP Panel, 2013)
concerning the reduction of the withdrawal time from 3 days to zero days and the introduction of
MRLs in edible tissues of chickens for fattening. In 2014, the Panel issued an opinion on a new
formulation (Avi-Deccox® 60G) of the additive (EFSA FEEDAP Panel, 2014).
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier6 in support of the authorisation request for the use of Deccox® as a feed additive. The
technical dossier was prepared following the provisions of Article 7 of Regulation (EC) No 1831/2003,
Regulation (EC) No 429/20087 and the applicable EFSA guidance documents.
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 On 27/09/2013 the applicant informed EFSA that the petitioner changed from Pﬁzer Ltd. to Zoetis Belgium SA, Rue Laid Burniat
1, 1348 Louvain-la-Neuve, Belgium.
3 Commission Regulation (EC) No 1289/2004 of 14 July 2004 concerning the authorisation for 10 years of the additive Deccox©
in feedingstuff, belonging to the group of coccidiostats and other medicinal substances, OJ L 243.15.7.2004, p. 15.
4 Commission Implementing Regulation (EU) No 291/2014 of 21 March 2014 amending Regulation (EC) No 1289/2004 as
regards the withdrawal time and maximum residue limits of the feed additive decoquinate. OJ L 87, 22.3.2014, p. 97.
5 Council Directive 70/524/EEC of 23 November 1970 concerning additives in feedingstuff, OJ L 270/1, p. 840.
6 FEED dossier reference: FAD-2013-0034.
7 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
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The FEEDAP Panel used the data provided by the applicant together with data from other sources,
such as previous risk assessments by EFSA or other expert bodies, peer-reviewed scientiﬁc papers, and
other scientiﬁc reports, to deliver the present output.
EFSA has veriﬁed the European Union Reference Laboratory (EURL) report as it relates to the
methods used for the control of the active substance in animal feed and marker residue in tissues. The
Executive Summary of the EURL report can be found in Annex A.8
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of Deccox®
(decoquinate) is in line with the principles laid down in Regulation (EC) No 429/2008 and the relevant
guidance documents: Guidance for the preparation of dossiers for coccidiostats and histomonostats
(EFSA FEEDAP Panel, 2011a), Technical guidance: Tolerance and efﬁcacy studies in target animals
(EFSA FEEDAP Panel, 2011b), Technical Guidance for assessing the safety of feed additives for the
environment (EFSA, 2008a), Guidance for the preparation of dossiers for the re-evaluation of certain
additives already authorised under Directive 70/524/EEC (EFSA, 2008b), Guidance for establishing the
safety of additives for the consumer (EFSA FEEDAP Panel, 2012a), Guidance on studies concerning the
safety of use of the additive for users/workers (EFSA FEEDAP Panel, 2012b) and Technical Guidance:
Microbial Studies (EFSA, 2008c).
3. Assessment
The current opinion is aimed at assessing the safety and efﬁcacy of the coccidiostat Deccox®
containing decoquinate as an active principle when used as a feed additive in chickens for fattening.
3.1. Characterisation
3.1.1. Characterisation of the additive
Deccox®, containing decoquinate (ethyl-6-decyloxy-7-ethoxy-4-hydroxyquinoline-3-carboxylate) as
an active substance, is intended to control coccidiosis caused by Eimeria spp. in chickens for fattening.
The additive is a blend of micronised decoquinate (60 g/kg) with colloidal silica (0.6 g/kg), soybean
oil (28.5 g/kg) and wheat middlings as carrier up to 1,000 g.
The analysis of ﬁve batches of Deccox® indicated product consistency; mean decoquinate content
was 62.5 g/kg (range: 62.2–62.7 g/kg).9
Data on impurities were provided for three batches of the additive.10 Results showed
concentrations of arsenic between < 0.020 and < 0.040 mg/kg, cadmium between 0.059 and
0.108 mg/kg, lead between 0.07 and 0.13 mg/kg and mercury below 0.005 mg/kg. Levels of aﬂatoxin
B1 were < 1 lg/kg, aﬂatoxins B2, G1, G2 (one batch) < 1 lg/kg. Dioxins (polychlorinated dibenzo-p-
dioxins and dibenzofurans (PCDD/F)) ranged between 0.14 and < 0.17 ng WHO-PCDD/F-TEQ/kg, and
the sum of dioxins and dioxin-like polychlorinated biphenyls (DL-PCBs) was between 0.28 and
< 0.49 ng WHO-PCDD/F-DL-PCB-TEQ/kg. Non-DL-PCBs were < 10 lg/kg in all three batches. Data on
microbial contamination was given for total aerobic count (49,000–220,000 cfu/g), for
Enterobacteriaceae (130–24,000 cfu/g), for Escherichia coli, (< 10 cfu/g), for Staphylococcus aureus
(< 10 cfu/g), for yeasts (< 10 cfu/g) and for moulds (100–1,200 cfu/g). Salmonella were absent in
25 g. None of these impurities are of concern. The Panel notes that the microbial contamination in
some batches is high.
Deccox® is a buff-coloured coarse powder preparation with an average density of 1,352 kg/m3 and
a bulk density of 408 kg/m3.11 Particle size distribution measured in ﬁve batches by sieve analysis
indicated that only a minor fraction of 0.1% (w/w) passed the 90 lm mesh.9 The dusting potential
(measured by Stauber–Heubach method in three batches) was 0.005 g/m3.12
8 The full report is available on the EURLwebsite: https://ec.europa.eu/jrc/sites/jrcsh/files/FinRep-FAD-2013-0034-Deccox.doc_.pdf
9 Technical dossier/Section II/Annex II.1.3.1.
10 Technical dossier/Section II/Annex II.1.4.1.3.
11 Technical dossier/Section II/Annex II.1.5.2.
12 Technical dossier/Supplementary information April 2015/Annex 1.1.
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3.1.2. Characterisation of the active substance
Decoquinate (ethyl-6-decyloxy-7-ethoxy-4-hydroxyquinoline-3-carboxylate, C24H35NO5, molecular
weight 417.6 g/mol, Chemical Abstracts Service No 18507-89-6), is a synthetic compound of the
quinoline family. Its structural formula is given in Figure 1.
Decoquinate is a cream to buff-coloured, microcrystalline powder with slight odour with a melting
point between 242 and 245°C.13 The applicant refers to three decoquinate-related impurities originating
from the chemical synthesis (tested routinely in the active substance). Total impurities are speciﬁed to
be < 2%. Individual speciﬁcations are given with < 0.5% for the impurity 6-decyloxy-7-ethoxy-4-
hydroxyquinoline-3-carboxylic acid, < 0.5% for diethyl-4-decyloxy-3-ethoxyanilinomethylenemalonate
(anilino compound) and < 1% for methyl-6-decyloxy-7-ethoxy-4-hydroxyquinoline-3-carboxylate. The
analytical data from ﬁve batches of the active substance conﬁrmed compliance with the speciﬁcations:
98.7–99.6% decoquinate, 0.08–0.11% 6-decyloxy-7-ethoxy-4-hydroxyquinoline-3-carboxylic acid,
< LOQ for the anilino compound and 0.14 to 0.23% for methyl-6-decyloxy-7-ethoxy-4-
hydroxyquinoline-3-carboxylate.14
The residual solvents were not detected in
ﬁve batches.14
3.1.3. Manufacturing process
The manufacturing process of the active substance via chemical synthesis is fully described in the
dossier.
3.1.4. Stability and homogeneity
3.1.4.1. Shelf-life of the additive
The stability of the additive (three batches) was investigated under long-term conditions (at 25°C/
60% relative humidity (RH)) up to 36 months and under accelerated conditions (at 40°C/75% RH up
to 6 months.15 After 36 months at long-term conditions, decoquinate recovery rate was 107%, 100%
and 100%, respectively, for the three batches. Recovery rates after 6 months at accelerated conditions
were 105, 93 and 107%.
Another study was carried out on three other batches to conﬁrm the stability data derived from the
above study under long-term conditions up to 36 months and under accelerated conditions up to
12 months.16 The content of decoquinate and related impurities (see Section 3.1.2) were measured.
After 36 months at long-term conditions, recovery rates ranged between 95% and 98%. Recovery
rates after 12 months under accelerated conditions were between 96% and 103%. No related
impurities were detected.
N
C
OH
O
O
O
H3C
H3C(CH2)9 O CH3
Figure 1: Structural formula of decoquinate
13 Technical dossier/Supplementary information April 2015/Annex 1.5
14 Technical dossier/Section II/Annex II.1.4.1.2.
15 Technical dossier/Section II/Annex II.4.1.1.1.
16 Technical dossier/Section II/Annex II.4.1.1.2.
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3.1.4.2. Stability of the additive in premixtures and feedingstuffs
The stability of decoquinate (one batch) was studied in a vitamin–mineral premixture (without
choline chloride, intended concentration 4,000 mg decoquinate/kg premixture)17 and in complete feed
(maize, soybean, pea type; intended concentration 20 mg decoquinate/kg feed)18 for chickens for
fattening. Samples were stored under long-term conditions (25°C/60% RH) and under accelerated
conditions (40°C/75% RH) (premixture only).
The analysed values for the premixture and the feed samples at 0 time point were below the
intended concentrations (3,731 mg/kg premixture and 18 mg mg/kg feed). The recovery rates in
premixture samples showed that decoquinate content decreased with time until 6 months under long-
term conditions (87% at 6 months). Results obtained later were unexpectedly higher (up to 106% at
18 months). A similar trend was noted when premixture samples were stored under accelerated
conditions: recovery rate was 62% after 1 month, followed by an increase which could not be
interpreted as an increasing stability. The recovery rates in feed samples appeared to be stable under
long-term conditions with values of 111%, 106% and 111% after 3, 6 and 12 weeks of storage.
3.1.4.3. Homogeneity
Samples from the premixture and the feed taken for stability studies were used to study the
homogeneous distribution of decoquinate in the respective batch. Decoquinate was analysed in eight
subsamples for the premixture and the complete feed (mash and pelleted). The coefﬁcient of variation
of the decoquinate concentration in the premixture was 2%, in the mash feed 5% and in the pelleted
feed 7%.
3.1.5. Conditions of use
Deccox® is a feed additive for the prevention of coccidiosis in chickens for fattening at a dose
range of 20–40 mg decoquinate/kg complete feed. The withdrawal period is zero day.
3.2. Safety
3.2.1. Safety for the target species
3.2.1.1. Tolerance study in chickens for fattening
A total of 240 one-day-old chickens (Ross) was randomly distributed to 4 groups (6 replicates of 5
birds per sex) and fed corn-soybean-type diets supplemented with 0, 40 (1x maximum proposed
dose), 200 (5x) and 400 (10x) mg decoquinate/kg for 35 days.19 A starter diet (crumbles, calculated
contents: 21.7% crude protein (CP), 12.8 MJ of metabolisable energy (ME)/kg) was given until day 21,
followed by a grower diet (pellets, calculated contents: 20% CP, 13.0 MJ ME/kg). The supplemented
feed used in the tolerance study contained 39, 203 and 389 mg decoquinate/kg starter diet and 50,
280 and 596 mg decoquinate/kg grower feed (for 40, 200 and 400 mg intended decoquinate/kg
complete feed, respectively).
Bird health, litter conditions and mortality were recorded daily. Body weight and feed consumption
were measured on days 0, 21 and 35 on a pen basis. Zootechnical parameters (average daily weight
gain, and feed to gain ratio) were calculated. On day 35 following ﬁnal pen weights, blood samples
were collected from one randomly selected bird per pen for haematology20 and clinical blood
chemistry.21 The same bird per pen was subsequently necropsied and selected tissues were collected
on day 35.
The pen was the experimental unit for statistical purposes. Statistical analyses using a general
linear mixed model were conducted at the 0.10 level of signiﬁcance using two-sided test.
17 Technical dossier/Section II/Annex II.4.1.2.1 and 4.1.2.2.
18 Technical dossier/Section II/Annex II.4.1.2.3 and 4.1.2.4.
19 Technical dossier/Supplementary information April 2015/Annex 2_1.
20 Red blood cell count (RBC), haemoglobin, haematocrit, mean corpuscular volume (MCV), mean corpuscular haemoglobin
(MCH), mean corpuscular haemoglobin concentration (MCHC), red cell distribution width (RDW), thrombocyte check,
eosinophils, heterophils, basophils, lymphocytes, monocytes.
21 Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH),
gamma-glutamyltranspeptidase (GGT), creatine kinase (CK), total protein (TP), total cholesterol, blood urea nitrogen (BUN),
uric acid, glucose, calcium, phosphorus, magnesium, sodium, potassium, chloride.
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No biologically relevant treatment effects were identiﬁed during the course of this study. There were
only four mortalities (one in each group) and two culls (one at 40 and another at 400 mg decoquinate/
kg). No statistically signiﬁcant differences were identiﬁed in any of the performance parameters
evaluated (means: 1,969 g body weight, 55 g average daily gain, 1.50 feed to gain ratio, and 84 g daily
feed intake) between any of the dose levels tested or when compared to the control group.
Gross pathology of necropsied bird organs did not identify any abnormal ﬁndings. There were no
statistically signiﬁcant differences between treatment groups in absolute organ weight for the bursa of
Fabricius, heart, kidneys, liver or spleen; and in organ weights relative to body weight for the heart,
kidneys and liver. Owing to the absence of ﬁndings by macroscopy, no histology was performed.
The statistically signiﬁcant differences identiﬁed in haematology (absolute eosinophils, absolute
heterophils, mean corpuscular haemoglobin concentration and red cell distribution width), serum
chemistry (gamma-glutamyl transferase and uric acid) and in organ weight relative to body weight
(bursa of Fabricius and spleen) were considered to be not biologically relevant as they were identiﬁed
in a non-dose dependent manner and/or were identiﬁed in only one sex.
The other haematology and the blood chemistry parameters were not affected by the treatment.
The results of this study indicate that about 400 mg decoquinate from Deccox®/kg feed – the
tenfold of the highest use level – were tolerated by chickens for fattening for 35 days.
The literature review made by the applicant for the time period 2000–2014 (Appendix A) identiﬁed
two publications in support of the safety of decoquinate for chickens for fattening.22
Zhou et al. (2009) investigated the safety of decoquinate as a liquid preparation (3 g decoquinate/
100 mL) administered to chickens (28-day-old Yangzhou AA chicken for fattening per group; average
body weight 119 g). The groups received water for drinking containing 0, 15, 45, 75 and 150 mg
decoquinate/L for 21 days. The decoquinate use level in water for drinking of 15 mg/L can directly be
compared with the applied highest use level in feed (40 mg/kg), the ratio of the two doses (2.67:1) is
within the range (2–3:1) given by the EFSA FEEDAP Panel Statement on the use of feed additives
authorised/applied for use in feed when supplied via water (EFSA FEEDAP Panel, 2010) for the ratio
water to feed intake. Parameters studied were body weight, feed consumption and feed to gain ratio,
haematology23 and clinical blood chemistry.24 At the end, chickens of the groups with 75 and 150 mg
decoquinate/mL water for drinking were slaughtered for necropsy (visual inspection, histology of liver
and kidney). The t-test was used for statistical examination of group differences.
Since feed consumption and feed composition were not reported and the study was conducted
without replicates, the results and particularly the performance data can be considered with
reservation only. Body weight gain and feed to gain ratio did not comply with data expected under
European husbandry conditions. The groups with 15, 45 and 75 mg decoquinate/L water for drinking
showed a signiﬁcant improvement of body weight gain at 21-day body weight gain (average about
361 g) and feed to gain ratio (average about 2.53) compared to the groups with 0 and 150 mg
(average about 262 g and 3.33, respectively). No signiﬁcant differences were seen in haematology and
clinical blood chemistry. At the end of the experiment, for some chickens (exact number not given) of
the group with 150 mg decoquinate/L water for drinking, mild clinically adverse reactions were
reported (mental depression, decreased feed intake and dishevelled feathers) and necrosis in renal
tubular epithelium and focal inﬂammatory cell inﬁltration in the liver. The data indicate that the ﬁvefold
overdose of decoquinate is tolerated by chickens for fattening.
Although the study does not comply with appropriate reporting, has several weaknesses in design
(lack of replicates, short duration) and cannot be considered to reﬂect European poultry management
conditions, the data provide worthwhile evidence of potential adverse side effects found by the clinical
examination and microscopical examination of liver and kidney, not performed in the tolerance study
provided by the applicant.
A second study found by literature search (Lee et al., 2012) was not considered since decoquinate
was not tested alone but in combination with certain drugs and the experimental criteria referred only
to the immune status.
22 Technical dossier/Supplementary information April 2015 Annex 5_I. Databases searched: Medline, Embase, Biosis, CAB
Abstracts, Derwent Veterinary Drug File, Agricola, Pascal, Toxcenter, SciSearch, Chemical Abstracts, Dissertation Abstracts,
ProQuest SciTech Collection; Period searched: until 2015.
23 RBC, lymphocytes, heterophils, eosinophils, basophils, monocytes, haemoglobin, MCH and platelet count.
24 Total protein, albumin, globulin, AST, ALT, LDH, ALP, glucose, BUN, creatinine, calcium, phosphorus, sodium, potassium and
chloride.
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3.2.1.2. Interactions
In its ﬁrst assessment, the FEEDAP Panel (EFSA, 2003) summarised that decoquinate, since its
introduction as a feed additive, has been extensively used in combination with a variety of other medicinal
compounds and ingredients in animal feed with only one incompatibility with bentonite reported.25 In the
only documented study in which compatibility was considered, no incompatibility between decoquinate
and the antibiotics chlortetracycline, oxytetracycline or spiramycin and furazolidone was found (Hodgson,
1968).
The applicant made a literature search for interactions of decoquinate with other additives and
veterinary drugs (Appendix A).26 Since no new ﬁndings were reported, the FEEDAP Panel maintains its
former conclusion that no incompatibilities or interactions with feedingstuffs, carriers, other approved
additives or medicinal drugs are expected with the exception of bentonite.
3.2.1.3. Microbial studies
The Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency
(EMA) acknowledged in 2000 (EMEA CVMP, 2000) that decoquinate does not have antibacterial action.
The FEEDAP Panel concluded in 2003 (EFSA, 2003) on a different database that decoquinate does not
have marked antibacterial properties.
For the current assessment, the FEEDAP Panel re-assessed the studies available in 200327 and
evaluated the outcome of the literature search28 on the emergence of resistance to decoquinate and
on the cross-resistance to antimicrobials performed by the applicant (Appendix A).29 Since no new
ﬁndings were reported, the FEEDAP Panel reiterates its former conclusion: ‘Most of the strains of
bacteria investigated occurring in the digestive tract of chickens appear resistant to the effects of
decoquinate at concentrations > 64 mg/L a concentration substantially higher than that expected in
the digestive tract of poultry. Consequently, effects on the bacterial ﬂora of chickens are likely to be
minimal. In the absence of demonstrable effects on the major species of gut bacteria it can be
reasonably concluded that the use of decoquinate would not select for strains resistant to clinically
important antibiotics or lead to the development of any form of cross-resistance’.
3.2.1.4. Conclusions on the safety for the target species
Based on a tolerance study and supported by a published safety study, the FEEDAP Panel concludes
that decoquinate from Deccox® is safe for chicken for fattening at the highest applied concentration in
complete feed of 40 mg/kg. The margin of safety is between 5 and 10.
No practically relevant interactions with other additives or veterinary drug exist except with
bentonite.
Decoquinate does not have antibacterial action.
3.2.2. Safety for the consumer
3.2.2.1. Absorption, distribution, metabolism, excretion and residues
For the present assessment, the applicant makes reference to the same studies assessed in the
former EFSA FEEDAP opinions (EFSA, 2003; EFSA FEEDAP Panel, 2013). An overview of the absorption,
distribution, metabolism, excretion and residues of decoquinate ﬁrstly assessed by the FEEDAP Panel in
2003 (EFSA, 2003) and then updated in 2013 (EFSA FEEDAP Panel, 2013) is given below.
In its previous opinion on the use of Deccox® for chickens for fattening (EFSA, 2003), the FEEDAP
Panel concluded that the limited studies made in chickens and laboratory animals effectively preclude
any comparison of the metabolic proﬁle of the chicken with those of the rat. However, the limited data
available indicates that there are differences in the number and nature of the metabolites produced in
the two species. As none of the metabolites have been identiﬁed or quantiﬁed (in either species), the
25 The United States FDA had recorded the incompatibility with bentonite used as a binder in pelleting. The FEEDAP Panel notes
that in a more recent FDA publication (e-CFR of March 23, 2017 § 558.195 Decoquinate as (d) Special considerations) it is
indicated that ‘Bentonite should not be used in decoquinate feeds’ (FDA (Federal Register on 12/27/2016) uses this warning
for decoquinate, robenidine and carbadox).
26 Technical dossier/Supplementary information April 2015/Annex 5_III.
27 Technical dossier/Supplementary information April 2015/3_2.
28 Databases searched: PubMed; time span: up to 2014.
29 Technical dossier/Supplemetary information April 2015/Annex 5_III.
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risk for the consumer exposed to decoquinate residues in chicken tissues cannot be adequately
assessed on the basis of the existing data.
For the assessment in 2013, the applicant submitted new metabolism/residue studies in the chicken
and rat, carried out using more advanced analytical tools (radio-high-performance liquid chromatography
(HPLC), liquid chromatography–mass spectrometry (LC–MS) and liquid chromatography–tandem mass
spectrometry (LC–MS/MS)) than in the former studies (EFSA, 2003). The same studies are submitted for
the current assessment.30
The FEEDAP Panel reiterates its previous conclusions:
i) Most of the radioactivity administered was recovered in the faeces (82–87%), urine being a
minor excretion route (0.2–0.4%). Decoquinate was the major component in the faeces (51
and 60% of the dose excreted in male and female animals, respectively).
ii) Tissue metabolic proﬁles showed that decoquinate was the major component in liver, kidney,
muscle, skin and fat (accounting for 19.6% of liver and kidney radioactivity and 23.9% of
muscle, 31.2% of skin and 76.5% of fat total radioactivity). Six metabolites, three of which
each accounted for more than 10% of total radioactivity, were isolated from the liver. One or
more of these metabolites were isolated from the other tissues.
iii) In terms of comparative metabolism, it appeared that the absorbed fraction of decoquinate is
metabolised more extensively in rat than in chicken, with the production of different
metabolites.
3.2.2.2. Toxicological studies
For the present assessment, the applicant makes reference to the same studies assessed in the
former EFSA FEEDAP opinions (EFSA, 2003 and EFSA FEEDAP Panel, 2013) and performed a literature
search on the toxicology of decoquinate (Appendix A).
An overview of the toxicological proﬁle of decoquinate ﬁrstly assessed by the FEEDAP Panel in 2003
(EFSA, 2003) and then updated in 2013 (EFSA FEEDAP Panel, 2013) is given below.
The mutagenicity studies presented for the assessment in 2003 were carried out in accordance with
Good Laboratory Practice (GLP) or were published in peer-reviewed journals, and the results suggested
that decoquinate is not genotoxic. A mouse lymphoma assay found that decoquinate caused gene
mutation in vitro at the highest concentration tested in the presence of metabolic activation, but it was
questionable whether it should be regarded as a positive result as most of the cells were killed at this
concentration. Other in vitro mutagenicity tests (Salmonella/microsome reverse mutation assay, a
bacterial rec assay and a cytogenetics test in mammalian cells) gave negative results.
An in vivo mammalian erythrocyte micronucleus test was submitted in for the assessment in 2013
and for the current assessment.31 Rats were given two daily intraperitoneal doses of up to 800 mg
decoquinate/kg body weight (bw) in accordance with OECD Guideline 474 and GLP. The study gave
negative results for genotoxicity.
Acute oral toxicity was low in rats. The repeated-dose oral toxicity studies and developmental
studies reported were done to standards appropriate to the time but some were not in accordance
either with GLP or with previous and current OECD guidelines. However, the quality of the studies was
considered sufﬁcient for the assessment. Repeat-dose oral toxicity studies were performed in rats
(several studies of duration 16 days to 2 years) and dogs (12-week and 2-year studies), with the
lowest no observed effect level (NOEL) seen in these studies being 15 mg/kg bw per day for subdued
behaviour in dogs given 62.5 mg/kg bw per day for 12 weeks. No adverse effects were seen in rats at
doses of up to 37.7 mg/kg bw per day for up to 2 years. No carcinogenicity studies were available, but
the two-year chronic toxicity study showed no effects on tumour incidences. A three-generation
reproduction study in rats showed no adverse effects up to the highest dose tested (60.6 mg/kg bw
per day). A rat developmental toxicity study showed fetotoxicity (retarded skeletal development) at
300 mg/kg bw per day, with a NOEL of 100 mg/kg bw per day, but showed no embryotoxicity or
teratogenicity. A rabbit developmental toxicity study showed embryotoxicity at 100 mg/kg bw per day,
with a NOEL of 60 mg/kg bw per day, but with no fetotoxic or teratogenic effects (EFSA, 2003).
No treatment-related adverse effects were seen in any of the studies at doses of 15 mg/kg bw per
day or less and this dose was therefore adopted as the overall NOEL.
30 Technical dossier/Section III/Annex_III_2_1_1_2 and 2_1_1_3.
31 Technical dossier/Section III/Annex_III_2_2_2_1.
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In the opinion in 2013, it was then concluded that: ‘The ADI of decoquinate, already established by
the FEEDAP Panel in 2003, is conﬁrmed. The value is 0.075 mg/kg bw based on the above NOEL,
applying an uncertainty factor of 200’.
The FEEDAP Panel noted that the literature search on the toxicology proﬁle of decoquinate did not
reveal any new data relevant to consumer safety and reiterates its previous conclusions.
3.2.2.3. Safety for the consumer
In 2013 the FEEDAP Panel noted that (EFSA FEEDAP Panel, 2013):
‘On the basis of new metabolism/residue studies in chicken and rat, major metabolites appeared to
be dissimilar in these two species. Nevertheless, the assessment of consumer safety refers to the
ADI of decoquinate, considering the limited exposure of consumers to metabolites from chicken
tissues. Decoquinate is the marker residue.
A conservative consumer exposure estimate based on total residues measured two or six hours
after withdrawal indicates that it would be about 2% of the ADI. Since a withdrawal period of two
or six hours corresponds to a withdrawal time of zero days under practical husbandry conditions, a
zero day withdrawal time does not compromise consumer safety.
The residue data submitted conﬁrm that no MRLs are considered necessary.’
In the absence of new data, the FEEDAP Panel conﬁrms its previous conclusions on the safety of
decoquinate for the consumer.
3.2.2.4. Conclusion on the safety for the consumer
Decoquinate is not genotoxic and is not carcinogenic. The lowest NOEL was 15 mg/kg bw per day,
observed in a 12-week oral toxicity study in dogs. The acceptable daily intake (ADI) is 0.075 mg
decoquinate/kg bw per day applying an uncertainty factor of 200 to the NOEL. No withdrawal period is
required to ensure consumer safety. No MRLs are considered necessary.
3.2.3. Safety for the user
No new study has been submitted by the applicant.
In a former opinion on Deccox® (EFSA, 2003), two inhalation toxicity studies in rats were assessed:
the studies were performed with the active substance (nose only) and did not show signs of irritation
up to the highest concentration in air (≥ 4 g/m3) after a 4–6 h exposure.
Deccox® was considered not irritant to skin and eyes and has no sensitisation potential. Recent
data conﬁrmed very low dusting potential of Deccox® (0.005 g/m3) (see Section 3.1.1).
The literature search provided by the applicant on the toxicology proﬁle of decoquinate did not
reveal any new data relevant to user safety (Appendix A).32
In line with its former assessment, the FEEDAP Panel concludes that exposure of users and workers
from handling the additive would be very low and inhalation risk for the user is considered negligible.
Deccox® is not irritant to skin and eyes and has no sensitisation potential.
3.2.4. Safety for the environment
The applicant made reference to the same studies assessed in a former EFSA FEEDAP opinion
(EFSA, 2003) with the addition of new studies. The previous studies, the new studies and the outcome
of a literature search performed by the applicant covering the period 2004–201433 were assessed by
the FEEDAP Panel following Regulation (EC) No 429/200834 and the FEEDAP technical guidance for
assessing the safety of feed additives for the environment (EFSA, 2008a).
32 Technical dossier/Supplementary information April 2015/Annex 5_IV; Databases searched: Medline, Embase, Biosis, CAB
Abstracts, Derwent Veterinary Drug File, Agricola, Pascal, Toxcenter, SciSearch, Chemical Abstracts, Dissertation Abstracts,
ProQuest Sci tech Collection. Period searched: until 2015.
33 Technical dossier/Supplementary information April 2015 Annex 5_V; Databases searched: Medline, Embase, Biosis, CAB
Abstracts, Derwent Veterinary Drug File, Agricola, Pascal, Toxcenter, SciSearch, Chemical Abstracts, Dissertation Abstracts,
ProQuest Sci tech Collection.
34 OJ L 133, 22.5.2008, p.1
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The active substance is not a physiological/natural substance of established safety for the
environment. Consequently, according to Regulation (EC) No 429/200834 the Phase I assessment has
to be continued to determine the predicted environmental concentration (PEC).
In Phase I and II initially, a total residues approach will be taken, meaning that the PECs will be
calculated, based on the assumption that the additive is excreted 100% as a parent compound.
3.2.4.1. Phase I
Physico-chemical properties of decoquinate
The physico-chemical properties of decoquinate are summarised in Table 1. The low vapour
pressure indicates that the substance will not volatilise to any great extent.
Fate and behaviour
No data were provided on the fate of decoquinate in manure. No information is available on the
hydrolysis or biodegradation of decoquinate in water.
Fate in soil
Adsorption
The adsorption of decoquinate to soil organic carbon (Koc) was measured in a GLP-compliant study
using [14C]-decoquinate and three soil types.35 However, preliminary solubility testing demonstrated
that decoquinate was insufﬁciently soluble in 0.01 M aqueous calcium chloride and as such, the OECD
106 guideline for adsorption/desorption was not used. Instead, the Koc determination was undertaken
for decoquinate in accordance with the screening method OECD guideline 121, in compliance with
GLP.36 The log Koc of decoquinate was estimated by comparing its retention time, using two different
mobile phases, to that of a range of substances for which log Koc values have been determined. Under
both sets of conditions, the retention time for decoquinate was longer than that for the most strongly
retained reference substance (DDT; log Koc = 5.63) and as such, it was established that the log Koc
value for decoquinate was > 5.63 (Koc = 426,580). OECD guideline 121 may provide unreliable Koc
values especially when log Koc > 5.63; nevertheless, the study highlight the very high adsorption
characteristics of the substance. Moreover, this very high adsorption characteristic is also highlighted in
the soil degradation study (see below). A Koc value of 400,000 L/kg is considered an appropriate
reference value for exposure calculation.
Degradation
The degradation of [14C]-decoquinate was investigated in two GLP-compliant studies. The older
one,37 from 2000, was performed to meet the regulatory requirements which were in force at the time
(Commission Directive 2001/79/EC). The rate and route of degradation were evaluated in sandy loam
soil treated with [14C]-decoquinate at an application rate of 1.28 mg/kg soil (dry weight); the rate of
degradation was determined in two further soil types (loamy sand and clay loam) at the same
application rate. The samples were incubated in the dark at 20°C for up to 120 days, under aerobic
conditions. The test system was maintained under negative pressure throughout the incubation period.
At intervals throughout the incubation period, samples were removed and extracted and the extracts
submitted to chromatographic analysis; non-extractable residues and volatile evolution were also
Table 1: Physico-chemical properties of decoquinate
Property Value Unit
Octanol/water partition coefﬁcient (log Kow 25°C)
(1) ≥ 5.7 at pH 5, 7, 9 –
Water solubility (20°C)(2) 0.06 mg/L
Dissociation constant pKa(3) – –
Vapour pressure(4) 3x109 Pa at 25°C
(1): Technical dossier/Section III/Annex III_4_1.
(2): EFSA, 2003.
(3): Technical dossier/Section III/Annex III_4_1.
(4): American Chemical Society, https://scifinder.cas.org.
35 Technical dossier/Section III/Annex III_4_1_Reference 17.
36 Technical dossier/Section III/Annex III_4_1_Reference 7.
37 Technical dossier/Section III/Annex III_4_1_Reference 16.
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quantiﬁed. Quantitative mass balance was obtained from the route soil (95–109% recovery). It was
evident from the outset that decoquinate, or its transformation products, adsorbed very strongly to
each of the soils under investigation, as freely extractable radioactivity only accounted for up to 9% of
that applied (ethanol was used as the extractant). By using a more vigorous extractant (1 M sodium
hydroxide and reﬂuxing), additional radioactivity was extracted from the samples, although this was
shown to vary over the course of the 120-day incubation period (up to 79%). Chromatographic
analysis of the radioactivity extracted from each soil sample indicated that decoquinate degraded to an
unidentiﬁed component, which accounted for 35–40% of applied radioactivity at study termination and
was more polar than the parent material. Two further minor unidentiﬁed components were also
detected (up to 5% of applied radioactivity). In each soil type, low levels of 14CO2 (up to 2% of
applied radioactivity) were released over the course of the incubation period, indicating that
decoquinate or its degradation products were not mineralised38 to a signiﬁcant extent. The DT50 values
for decoquinate transformation were estimated to be 96, 116 and 140 days. DT90 values could not be
reliably calculated, but it is evident that decoquinate is transformed in soil. However, as it cannot be
demonstrated experimentally that the DT90 value of decoquinate in soil is less than 1 year, the
potential for residues to accumulate in soil will be factored into the environmental risk assessment.
The aerobic degradation of [14C]-decoquinate in loamy sand and clay loam soil was examined in a
new GLP-compliant study39 investigating the contribution and nature of the transformation products of
[14C]-decoquinate formed in soil (OECD guideline 307). The aim of the study was to relate the ﬁndings
of the new study with those from the old study described above. [14C]-Decoquinate was applied at a
nominal concentration of 1.28 mg/kg dry weight soil to the same soil types as in the study above. The
soils were incubated under aerobic conditions and maintained in the dark at about 50% maximum
water holding capacity at 20  2°C for up to 120 days (re-calculate at 12°C). For each soil, duplicate
samples were taken for analysis at 0, 14, 28, 42, 56, 70, 91 and 120 days after treatment. At each
sampling time, samples were extracted and analysed for decoquinate, degradation products and non-
extractable residues. Any volatile radioactivity was continuously ﬂushed from the vessels and collected
in traps. A mass balance was determined for each sample.
The mean mass balance in loamy sand and clay loam was 97% and 100% of applied radioactivity,
respectively. Radioactivity recovered in organic soil extracts declined slightly as the incubation
progressed, but was much improved compared with that observed in the ﬁrst study, particularly in the
early sampling intervals. In loamy sand, 101% of applied radioactivity was extracted at day 0,
decreasing to 78% at day 120 and in clay loam, 102% of applied radioactivity was extracted at day 0,
decreasing to 65% at day 120. A concurrent increase in non-extractable residues was evident,
accounting for means of 15% and 30% at day 120 in loamy sand and clay loam, respectively.
Subsequent organic matter fractionation of these residues demonstrated that most of the radioactivity
was associated with the humin fraction (up to 23%). Radioactivity evolved as 14CO2 non-speciﬁc
organic [14C]-volatile compounds was negligible (< 0.4%), which demonstrates that decoquinate and
its degradation products are not mineralised in soil.
Combined sample extracts were submitted for chromatographic analysis using HPLC. For both soils,
[14C]-decoquinate was the principal component detected at day 0, accounting for 100% of applied
radioactivity in loamy sand and 102% in clay loam. [14C]-Decoquinate levels declined as the incubation
progressed, accounting for 52% and 53% at day 120 in loamy sand and clay loam, respectively. The
degradation slowed down signiﬁcantly during the experiments; however, the decline from day 56 to
the end of the study was very much lower than the initial decline.
A number of minor unknown components (up to 12) were detected as the incubation progressed in
each of the soils. With the exception of a single soil sample (day 70 loamy sand, replicate B), each of
the unknown components represented less than 10% of applied radioactivity. Concentrations of the
degradation products were too low to permit structural identiﬁcation.
The results of the new study correlate well with the old study and show that decoquinate is partly
transformed to a number of degradation products, which are not mineralised in soil. Considering both
studies the DT50 of decoquinate transformation in soil ranges between 96 and 140 days.
Very hydrophobic substances like decoquinate might sorb so strongly to soil that the degradation is
hampered. In this case, the highest DT50 is selected for further calculations since degradation is absent
or extremely slow after more than 56 days of incubation.
38 Degradation to CO2, salts and water.
39 Technical dossier/Supplementary information September 2016/Annex 2.
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When the DT50 of 140 days is adjusted to an incubation temperature of 12°C using the Arrhenius
equation,40 the new DT50 is about 300 days, which will be used for further calculations.
Conclusion on fate and behaviour
A Koc of 400,000 is used for the further risk assessment.
Decoquinate is not mineralised in soil. A DT50 for transformation of decoquinate of 300 days is used
for further calculations.
Predicted environmental concentrations
The methodology for the calculation of the maximum PEC soil, groundwater and surface water are
described in the technical guidance for assessing the safety of feed additives for the environment (EFSA,
2008a). For a highly persistent compound like decoquinate, a reﬁned PEC in soil should be used according
to the guidance, giving a PECplateau in soil, groundwater, surface water and sediment (Table 2).
The Phase I PEC trigger value for soil is exceeded. Therefore, a Phase II assessment is considered
necessary. Predicted concentration in groundwater is below the trigger value of 0.1 lg/L. No further
reﬁnement is necessary for this compartment.
3.2.4.2. Phase II
Effect assessment – Ecotoxicity studies
Toxicity to terrestrial compartment
Effects on plants
The effect of decoquinate on terrestrial plants was investigated in a GLP-compliant study;41 the
study followed the OECD guideline 208 which was in force at the time the study was conducted.
The FEEDAP Panel noted that although there are some minor experimental differences compared with
the current OECD guideline design, the results from the study are adequate to assess any impact
which decoquinate might have on the emergence and growth of terrestrial plants. The study was
conducted using a sandy loam soil and three plant species: wheat, mustard and mung beans. The LC50
for emergence and the EC50 for growth were higher than the highest concentration tested (100 mg/kg
dry weight soil) for each of the species evaluated.
Effect on earthworms
The acute toxicity of decoquinate to Eisenia foetida andrei was tested at a limit nominal rate of
1,000 mg/kg soil in a 14 days study at 20°C.42 An artiﬁcial soil was used composed of 70% sand, 20%
Table 2: Initial plateau predicted environmental concentrations of decoquinate in soil (lg/kg),
groundwater, surface water (lg/L) and sediment (lg/kg dry weight)
Input Value
Dose (mg/kg decoquinate in feed) 40
Molecular weight (decoquinate) 417.53
VP (Pa) 3.3E-9
Solubility (mg/L) 0.06
Koc (L/kg) 400,000
DT50 at 12°C (days) 300
Output
PECsoil 365
PECgroundwater 0.052
PECsurfacewater 0.017
PECsediment 345
40 The temperature correction was performed according to the scientiﬁc opinion of the Panel on Plant Protection Products and
their Residues on a request from EFSA related to the default Q10 value used to describe the temperature effect on
transformation rates of pesticides in soil (EFSA, 2007).
41 Technical dossier/Section III/Annex III_4_1_Reference 19.
42 Technical dossier/Section III/Annex III_4_1_Reference 20.
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kaolinite clay and 10% sphagnum moss peat. No mortality or abnormal behaviour was observed.
Though, the weight was signiﬁcantly reduced by 12%, indicating that decoquinate can have an effect
on the weight loss at the concentrations of 1,000 mg/kg.
The effect of decoquinate on the reproductive performance of earthworms was investigated in a 56
day GLP-compliant study,43 based on a draft OECD guidance which was available at the time the study
was conducted.44 The FEEDAP Panel noted that some minor differences exist between this study and
the current OECD guideline 222 reproduction study test design, but these are not considered to impact
on the results obtained. Earthworms were exposed to decoquinate in artiﬁcial soil over a 28-day
exposure period, at nominal concentrations equivalent to 62.5, 125, 250, 500 and 1,000 mg/kg dry
soil. The nominal concentrations were not veriﬁed by chemical analysis. Adult earthworms were
removed from test soil and assessed for mortality, weight change and sublethal effects after 28 days
of exposure. Soil was replaced in the test container and juveniles were allowed to grow for a further
28 days, after which time they were removed from the soil, counted and sub-lethal effects assessed.
No signiﬁcant adult mortality was noted during the test, nor effects on adult body weight. The FEEDAP
Panel noted that during the test, clean manure was added to feed the worms. This is not
representable for the situation in the ﬁeld, where coccidiostats are added via the manure.
Reproduction was reduced at 250 mg/kg, but no such effect was evident in the higher decoquinate
treatments (500 and 1,000 mg/kg). The no observed effect concentration (NOEC) for reproduction is
1,000 mg/kg.
Effects on soil microorganisms
The effect of decoquinate on soil nitrogen transformations was investigated in a GLP-compliant
study (OECD guideline 216).45 The possible effects of decoquinate on soil microﬂora under aerobic
conditions were studied upon the short-term respiration and nitrogen transformation. The test
substance was incorporated into the sandy loam soil at concentrations of 1.839 and 9.195 mg/kg of
decoquinate.46 At the day 28 after the treatment, concentrations of nitrate in decoquinate-treated soil
at the concentrations tested deviated from the control by less than 25%. No prolonged effects could
be expected when using decoquinate as additive for chickens for fattening.
Toxicity to aquatic organisms
Effects on algae
The effect of decoquinate to the algal species Raphidocelis subcapitata (former names:
Selenastrum capricornutum, Pseudokirchneriella subcapitata) was determined at a limit nominal
concentration of 100 mg/L following the OECD guidelines 201.47 At the beginning of the test (after
ﬁltration), the solubility of the decoquinate was analysed in six parallel samples resulting the highest
concentration of 0.234 mg/L, which is far above the reported water solubility. After 72 h, the
concentration of the tested substance was below limit of quantiﬁcation (LOQ) of 0.039 mg/L.
Undissolved material was present in the test system. After 72 h, no signiﬁcant effect on growth rate
could be estimated leading to the conclusion that the NOEC is equal to the highest obtained soluble
concentration of decoquinate in the test (0.234 mg/L). However, the applicant claims, that the
solubility of the decoquinate in the test was overestimated. The recalculation of solubility of tested
substance was provided as a time-weighted mean resulting in highest solubility concentration of
0.073 mg/L and the NOEC value of 0.073 mg/L (73 lg/L).48
Effects on crustaceans
The acute toxicity of decoquinate to Daphnia magna, under semi-static conditions, was investigated
following the OECD guideline 202.49 As decoquinate was shown not to be toxic in the range ﬁnding
phase of the study, the deﬁnitive phase was conducted as a limit test. Due to the very limited aqueous
solubility of decoquinate, only very low concentrations of decoquinate could be assessed for toxicity. A
saturated solution was prepared by ultra-sonication of excess decoquinate in daphnid medium
43 Technical dossier/Section III/Annex III_4_1_Reference 21.
44 OECD Draft Guideline Earthworm Reproduction Test (2000), BBA Guideline Part VI 2-2 (1994) and ISO Guideline 11268-2
(1998) Part 2.
45 Technical dossier/Section III/Annex III_4_1_Reference 18.
46 The values taken for the studies were considered as PEC and 5*PEC by the applicant at the time when conducting the study.
47 Technical dossier/Section III/Annex III_4_1_Reference 24.
48 Technical dossier/Section III/Annex III_4_1_Reference 23.
49 Technical dossier/Section III/Annex III_4_1_Reference 22.
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(nominally 100 mg/L), prior to the addition of the test organisms. Daphnids were exposed over a 48 h
exposure period, under semi-static conditions (24 h replacements). The aqueous soluble fraction
(prepared following ﬁltration) was determined at intervals during the study by HPLC. However, the
measured concentration of decoquinate was noted to decline between medium changes and as such,
the EC50 and NOEC values were calculated in terms of maximum achievable solubility. These results
were subsequently recalculated in terms of time-weighted means48 and these values have been used
for risk assessment purposes. Under the conditions of the study, the EC50 value for decoquinate was
reported as > 0.034 mg/L, based on the time-weighted mean.
The effect of [14C]-decoquinate on the reproductive capacity of D. magna was investigated
following the OECD guideline 211 in a GLP-compliant study.50 The study was conducted over a 21-day
exposure period, under semi-static conditions with test solutions renewed three times per week. A
range ﬁnding test indicated that the exposure concentrations were nominally 6, 10, 17, 29 and 50 lg/L
of decoquinate, in addition to untreated and solvent control groups. No precipitation of [14C]-
decoquinate was observed in any of the test vessels during the study. Analysis of test samples from
the deﬁnitive test in freshly prepared solutions and on days 3, 5, 7, 10, 12, 14, 17, 19 and 21 in
expired solutions indicated that concentrations of [14C]-decoquinate were not maintained within 20%
of the initial measured values. The corresponding geometric mean measured concentrations of [14C]-
decoquinate were 4.33, 7.57, 14.47, 22.84 and 35.25 lg/L. As such, the results of the reproduction
test were based on the geometric mean measured concentration of [14C]-decoquinate.
During the reproduction test, one (10%) immobile adult D. magna was recorded in the 4.33 lg/L
treatment group. Offspring from the adult which died during the test were omitted from the
calculation of total number of offspring and mean number of offspring per test animal. First offspring
were observed in treatment groups, in the control, and in the solvent control on the day 8 and on the
day 9 of the test.
During the reproduction test, test solution quality parameters were examined and found within the
required ranges and validity criteria for a valid test were also met.
The lack of signiﬁcant adult immobilisation or reduction in offspring production indicated that
exposure to [14C]-decoquinate over a 21-day period had no effect on D. magna survival and
reproduction at any of the tested concentrations. The 21-day EC50 for [
14C]-decoquinate for
reproduction in D. magna was therefore concluded to be > 35.25 lg/L and the 21-day NOEC was
determined as 35.25 lg/L, based on geometric mean measured concentrations.
Effects on ﬁsh
The acute toxicity of decoquinate to rainbow trout Oncorhynchus mykiss was determined under
semi-static conditions at a nominal concentration of 100 mg/L decoquinate according to OECD
guideline 203.51 Test solutions were ultrasonicated for 10 minutes to achieve the maximum soluble
concentration. Test solutions were replaced after 24 h. The test solutions appeared opaque and off-
white colour with small quantities at the surface. Excess undissolved material was retained in the test
system. At the start (after ﬁltration), a concentration was measured of 0.040 mg/L decoquinate. After
24 h, the concentration was below the limit of detection (LOD) (0.008 mg/L). After 96 h, no mortality
was observed. The EC50 was ≥ 16 lg/L (time weighted average).
48
Effect on sediment dwelling organisms
The toxicity of decoquinate to chironomids was investigated in a GLP-compliant study, using sediment
which had been fortiﬁed with [14C]-decoquinate.52 The test design was based on draft guidance which
was available at the time study was initiated.53 The FEEDAP Panel noted that some minor differences
exist between this study and the current OECD guideline 233 on spiked sediment toxicity test design, but
these are not considered to have an impact on the results obtained from this study.
A preliminary range ﬁnding phase was conducted with non-radiolabelled decoquinate and no effects
were evident at the highest sediment concentration which was tested (1,000 mg/kg dry weight). The
applicant noted that, although conventionally, 1,000 mg/kg would have been selected as the exposure
concentration for the deﬁnitive limit test, nominal concentration equivalent to 10 times the preliminary
50 Technical dossier/Supplementary information September 2016/Annex 1.
51 Technical dossier/Section III/Annex III_4_1_Reference 25.
52 Technical dossier/Section III/Annex III_4_1_Reference 26.
53 OECD Draft Guideline: Chironomid Toxicity Test using Spiked Sediment (2002) and BBA Final Draft Guideline: Effect of Plant
Protection Products on the Development of Sediment Dwelling Larvae of Chironomus riparius in a Water Sediment System
(1995).
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PEC (18 mg/kg) would provide the required LOD for aqueous samples, while also providing adequate
data on the toxicity of decoquinate to chironomids.
Chironomus riparius larvae were exposed to [14C]-decoquinate, adsorbed to quartz sand as a
carrier, at an actual concentration of 16.3 mg/kg sediment (dry weight basis), over a 28-day period,
under static conditions. The number and sex of emerged adult chironomids were recorded daily during
the exposure period. The distribution of radioactivity in the test system at day 0, 7 and 28 was
determined by measuring levels of radioactivity in the sediment, interstitial and overlying water. Mass
balance was demonstrated to be quantitative.
No signiﬁcant differences were observed between the emergence ratio and development rate of the
solvent control (chloroform) and decoquinate treatment. Statistically, 16.3 mg/kg was conﬁrmed as the
NOEC; however, the results of the range ﬁnding phase indicated that the NOEC was 1,000 mg/kg. For
the risk assessment, the NOEC for decoquinate has been conservatively assigned as 16.3 mg/kg (dry
weight basis), thus providing a considerable margin of safety.
Conclusions on the ecotoxic effect on soil, water and sediment
The applicant submitted studies which followed OECD guidelines (or other appropriate standardised
methods) as proposed in the technical guidance for assessing the safety of feed additives for the
environment (EFSA, 2008a). Tests, with the exception of test on earthworm reproduction, are valid
and the test results can be accepted and used for determination of predicted no effect concentrations
(PNECs) and to establish the safe values for exposed environmental compartments.
For the terrestrial compartment, data are available for microorganisms, earthworms and plants.
Risk for terrestrial compartment was evaluated based on the acute effect in earthworm at the limit test
of 1,000 mg/kg soil applying an assessment factor (AF) of 1,000 (Table 3). For the aquatic
compartment, data are available for algae, aquatic invertebrates and ﬁsh. The lowest toxicity value for
the aquatic compartment was found in a study on effect on reproduction of daphnids. A safety factor
of 50 was used to derive the PNEC for aquatic organism (Table 4).
Ecotoxicological data for sediment-dwelling invertebrates are provided for the sediment
compartment. The calculated PNEC for the risk assessment is 1,630 lg/kg decoquinate, applying an
AF of 10 to the NOEC of 16.3 mg/kg (Table 5).
Risk characterisation (PEC/PNEC ratio)
The risk characterisation ratios for terrestrial, freshwater and sediment compartments are reported
in Tables 3, 4 and 5, respectively.
Table 3: Risk characterisation (PEC/PNEC ratio) of decoquinate for terrestrial compartment
Taxa PECsoil (lg/kg)
EC50/LC50/NOEC
(mg/kg)
AF
PNEC
(lg/kg)
PEC/PNEC
Earthworm 365 1,000(1) 1,000 1,000 0.4
Plants > 100(2) 100 > 1,000 0.4
AF: assessment factor.
(1): NOEC.
(2): EC50 and LC50.
Table 4: Risk characterisation (PEC/PNEC ratio) of decoquinate for freshwater compartment
Taxa
PECsurfacewater
(lg/L)
EC50/LC50/NOEC
(lg/L)
AF
PNEC
(lg/L)
PEC/PNEC
Algae
Raphidocelis subcapitata
0.017 73(1) 50 1.5 0.01
Aquatic invertebrates
Daphnia magna
35(1) 50 0.7 0.02
Fish
Brachydanio rerio
≥ 16(2) 50 > 0.16 0.11
AF: assessment factor.
(1): NOEC.
(2): EC50 and LC50.
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Bioaccumulation of decoquinate
A GLP-compliant study based on the OECD guideline 317 was conducted on [14C]-decoquinate and
a non-radiolabelled decoquinate spiked onto the artiﬁcial soil.54 Earthworms were exposed to the test
substance at mean measured concentration of 10.24 mg/kg dry soil during the 21 days of uptake
period. The uptake was followed by the 21 days of elimination phase. Coefﬁcient of variation of
measured concentrations of decoquinate in the series of samples did not exceed 15% at any sampling
day. Earthworms and soil samples from the test trials were regularly sampled throughout the course of
the study and analysed for the content of decoquinate, the mortality, weight change and behaviour.
The concentration of decoquinate (or its equivalents) was constant during the uptake phase, ranging
from 9.7 to 10.8 mg/kg soil (dry weight). Limited uptake of decoquinate (or its equivalents) was
evident in earthworms during the uptake phase and concentrations ranged from 0.20 to 0.50 lg
equivalents/g tissue wet weight basis. The calculated bioaccumulation factor (BAF) was the highest at
day 2 (BAF of 0.27 calculated on wet weight basis); after day 14, the BAF was lowered to 0.11–0.15
wet weight. The plateau was reached in a few hours after the beginning of exposure. During the
elimination phase, concentrations of decoquinate equivalents quickly declined and within 5 h (ﬁrst
sampling interval in the elimination phase) were below the LOD (0.05 lg equivalents/g tissue wet
weight basis). At the end of the 21-day exposure period, a BAF of about 0.03 (wet weight) was
established.
3.2.4.3. Conclusions on safety for the environment
The PEC/PNEC ratios for terrestrial, aquatic compartment and sediment are below 1, indicating that
decoquinate used in chickens for fattening up to the highest proposed dose, does not pose a risk for
these compartments; as well, no risk is expected neither for secondary poisoning nor for groundwater
contamination.
The literature search provided by the applicant on decoquinate did not reveal any new data
relevant to the safety for the environment.
3.3. Efﬁcacy
For coccidiostats under re-evaluation, efﬁcacy data should derive from two types of target animal
experiments: a) natural/artiﬁcial infection to simulate use conditions (e.g., ﬂoor pen studies with
poultry), at least one of the locations should be in the EU, b) actual use conditions in ﬁeld trials, all
should be done in the EU within the last 5 years. Anticoccidial sensitivity tests (AST) could replace ﬁeld
trials provided they meet the criteria mentioned in the relevant guidance document on coccidiostats
and histomonostats (EFSA FEEDAP Panel, 2011a).55
3.3.1. Floor pen studies
Three ﬂoor pen studies in chickens for fattening were submitted.56 Birds were penned and
distributed into treatment groups as indicated in Table 6.57 Treated groups received feed containing
20 mg decoquinate/kg feed; dosage was analytically conﬁrmed. Infected groups were inoculated with
Table 5: Risk characterisation (PEC/PNEC ratio) of decoquinate for sediment
Taxa
PECsediment
(lg/kg)
NOEC
(mg/kg)
AF
PNEC
(lg/kg)
PEC/PNEC
Sediment-dwelling invertebrates
Chironomus riparius
342 16.3 10 1,630 0.21
AF: assessment factor.
54 Technical dossier/Section III/Annex III_4_2_5_1.
55 The FEEDAP Panel stated in its guidance for the preparation of dossiers for coccidiostats and histomonostats (EFSA FEEDAP
Panel, 2011a) that studies with artiﬁcial infection would be preferred over ﬁeld trials due to their inherent weaknesses. These
short term studies should use ﬁeld strains of Eimeria, recently conﬁrmed as pathogenic/resistant by a sensitivity test or
recognised problems in the poultry operation (conﬁrmed by veterinary certiﬁcate). The Eimeria ﬁeld strains should ideally
undergo one, but in any case not more than two passage(s) before use in such trials.
56 Trial 1: Technical dossier/Section IV/Annex IV.2.4. Trial 2: Technical dossier/Section IV/Annex IV.2.5. and Trial 3: Technical
dossier/Section IV/Annex IV.2.6.
57 Trial 1: male and female chickens, strain not indicated Trial 2: male chickens Ross 308 Trial 3: male chickens Cobb 500.
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recent ﬁeld isolates of pathogenic Eimeria species (see Table 7 for details). Animal health and mortality
were monitored daily. Feed intake and body weight of the animals were measured throughout the
study, feed to gain ratio was calculated. Samples of excreta were analysed for oocyst excretion and
intestinal lesions were scored on ﬁve animals per pen following the method of Johnson and Reid
(1970) (0 = no lesion, 1 = very mild, 2 = mild, 3 = moderate and 4 = severe).
In trial 1, mortality data was statistically analysed by chi-square test, lesion scores by Mann–
Whitney U-test and all other parameters by analysis of variance (ANOVA). In trials 2 and 3, data were
statistically analysed using a general linear mixed model. Pair-wise treatment comparisons were made
if the general analysis indicated signiﬁcance. In all trials, the hypothesis tests were conducted at the
0.05 level of signiﬁcance using two-sided tests.
Table 7: Summary of inoculation in ﬂoor pen studies performed with Deccox®
Trial
Start
Date
Inoculum characteristics
Month/Year and country
of isolation
Intended dose per bird
(oocysts)
Day and mode of
inoculation
1 6/2011 3/2010
Spain
1.2 9 105 E. acervulina Day 15
via gavage2.5 9 104 E. praecox
1.3 9 104 E. tenella
1.2 9 104 E. maxima
2 6/2012 9/2010
The Netherlands
5.3 9 104 E. acervulina Day 14
via gavage1.1 9 104 E. tenella
1.1 9 104 E. maxima
2.6 9 103 E. mitis
4.0 9 102 E. necatrix/E. praecox
3 6/2012 4/2012
Germany
1.5 9 103 E. acervulina Day 14
via gavage5.0 9 102 E. maxima
8.0 9 103 E. tenella
Table 6: Experimental design of ﬂoor pen studies performed with Deccox®
Trial
Study
Duration
(days)
Replicates per
treatment
(birds per
replicate)
Test animal Treatment groups
Analysed
decoquinate
(mg/kg feed)(2)
1 35(1) 8
(30)
Male and female
chickens Strain not
indicated
Infected untreated control
group (IUC)
–
Infected treated group (IT) 17.9
2 35 12
(30)
Male chickens Ross
308
Uninfected untreated control
group (UUC)
–
Infected untreated control
group (IUC)
–
Uninfected treated group
(UT)
16.3/18.8
Infected treated group (IT) 16.3/18.8
3 35 12
(30)
Male chickens Cobb
500
Uninfected untreated control
group (UUC)
–
Infected untreated control
group (IUC)
–
Uninfected treated group
(UT)
20/23.6/23.7
Infected treated group (IT) 20/23.6/23.7
(1): Starting with 8-day-old chicken.
(2): In trial 1, starter feed was administered throughout the study. In trial 2, birds received starter diet from day 0 to 21, grower
diet from day 21 to 35. In trial 3, birds received starter diet from day 0 to 14, grower diet from day 14 to 28 and ﬁnisher
diet from 28 to 35.
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Coccidiosis-related endpoints in ﬂoor pen trials are summarised in Tables 8, 9, 10 and 11;
performance data and mortality are summarised in Table 12.
Table 8: Total number of Eimeria oocysts per gram of excreta (OPG) in ﬂoor pen studies
Trial 1 Day 22 Day 24 Day 29 Day 36 Day 43
IUC 2,500,000 300,000 36,000 8,100 6,000
IT 89,000* 640,000 85,000 5,900 6,600
Trial 2 Day 17 Day 21 Day 23 Day 28 Day 30 Day 32 Day 35
UUC 0 6 1 261 130 114 688
IUC 2 115,410 17,113 9,791 27,734 11,851 10,492
UT 1 6 9 1,771 255 120 69
IT 0 129,093 7,502 2,664 3,231* 6,708 631*
Trial 3 Day 17 Day 21 Day 23 Day 28 Day 30 Day 32 Day 35
UUC 0 0 0 0 0 0 0
IUC 0 60,975 64,985 1,490 794 213 37
UT 0 0 0 0 0 1 0
IT 0 174,943 65,321 466 230 230 87
IT group mean with * is signiﬁcantly different from IUC group mean (p ≤ 0.05).
Table 10: Mean lesion scores in ﬂoor pen trial 2
Day
Duodenum and upper
small intestine
Lower small intestine Caecum
21 28 21 28 21 28
UUC 2.4 2.9 1.7 1.9 1.6 1.8
IUC 2.6 3.1 1.8 1.9 1.9 2.2
UTC 2.4 3.0 1.6 1.9 1.6 1.7
IT 2.7 3.0 1.7 1.9 1.6 1.7
No statistical analysis was performed on the mean values.
Table 9: Mean lesion scores in ﬂoor pen trial 1
Day
E. acervulina E. tenella E. maxima
22 29 43 22 29 43 22 29 43
IUC 2.03 0.20 0.10 3.65 0.15 0.05 0.63 0.23 0
IT 0.60* 1.05* 0 1.55* 0.33 0.03 0.40 0.08 0
IT group mean with * is signiﬁcantly different from IUC group mean (p ≤ 0.05).
Table 11: Mean lesion scores in ﬂoor pen trial 3
Day
Duodenum and upper
small intestine
Lower small intestine Caecum
21 28 21 28 21 28
UUC 0 0 0 0 0 0
IUC 0.5 1.3 0 0.7 0 0.3
UTC 0 0 0 0 0 0
IT 1.4 0.4 0.1 0.2 0.2 0
No statistical analysis was performed on the mean values.
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In trial 1, decoquinate at 20 mg/kg feed reduced signiﬁcantly coccidiosis-related mortality. Highest
OPG (oocysts per gram of excreta) values were found 7 days after inoculation; decoquinate reduced
signiﬁcantly OPG compared to the untreated group (Table 8). No signiﬁcant differences were found at
the following examination days. No E. maxima oocysts were found in the excreta of the treated group
7 and 9 days after inoculation compared to the untreated group (1.6 9 104 and 2.5 9 103,
respectively). The E. maxima oocyst excretion remained at a lower level, although not signiﬁcant, for
the rest of the observation period.
Lesions were separately recorded for three Eimeria species of the inoculum. Mean lesion scores for
E. acervulina and E. tenella species were signiﬁcantly lower 7 days after inoculation in the treated
group. E. acervulina lesion score 14 days after inoculation was signiﬁcantly higher in the treated
group. There was a tendency for lower lesion scores 28 days after inoculation in the treated group
(Table 9).
Cumulative feed intake and ﬁnal body weight were signiﬁcantly higher in IT group than in IUC
group. Feed to gain ratios were not signiﬁcantly inﬂuenced by the treatment. Body weight gains were
signiﬁcantly higher in IT group than in IUC group (Table 12).
In trial 2, mortality/culls did not differ signiﬁcantly among groups (overall mean 4.3%). Higher OPG
values from day 7 after inoculation until the end of the study were characteristic for the infected
groups. The OPG values reached a peak 7 days after inoculation with no differences between IUC and
IT groups. All later observations found OPG values at a level of about 10–25% of the peak OPG.
Signiﬁcantly reduced OPGs by the treatment were found 16 and 21 days after inoculation (Table 8).
The presence of blood in faeces was ﬁrst observed in 8 pens of the IUC group 14 days after
inoculation followed by 7 and 9 pen observations 1 and 2 days later, respectively. In contrast to that,
bloody faeces were found in the IT group only in 4 and 1 pens 14 and 16 days after inoculation,
respectively.
Lesions were recorded 7 and 14 days after inoculation for the duodenum and upper small intestine,
lower small intestine and caecum. The mean values were at the same level for all four groups
(Table 10). Considering the frequency of the single lesion scores, the only signiﬁcant difference in
favour of the treatment was found for lesion score 3 in the caecum on both observation days.
The 35-day body weight and feed to gain ratio of all groups were nearly the same (overall mean
2,249 g and 1.45) without differences between the IUC and IT groups (Table 12).
Trial 3 showed high mortality already in the uninfected groups (mean 10.3%). Infection resulted in
an increase of mortality (15.3%) without a positive effect of the treatment. No signiﬁcant differences
Table 12: Performance data and mortality of chickens in ﬂoor pen trials with Deccox®
Feed Intake(1)
(g)
Body weight
(g)
Weight Gain(2)
(g)
Feed to gain
ratio(3)
Mortality
n (%)
Trial 1
IUC 39,550 998 887 2.0 17 (7.1)
IT 45,800* 1,074* 963* 2.0 1 (0.4)*1
Trial 2
UUC 92.5 2.267 64 1.44 14 (3.9)
IUC 91.6 2.228 63 1.47 17 (4.7)
UTC 92.1 2.274 64 1.43 17 (4.7)
IT 90.3 2.225 62 1.46 14 (3.9)1
Trial 31
UUC 98.6 2.204 62 1.60 32 (8.9)
IUC 95.7 2.059 58 1.66 52 (14.4)
UTC 97.9 2.225 62 1.58 42 (11.7)
IT 91.5* 2.014 56 1.64 58 (16.1)
IT group mean with * is signiﬁcantly different from IUC group mean (p ≤ 0.05).
(1): Results of trials 2 and 3 refer to daily feed intake, results of trial 1 refer to total feed intake (day 8–43) per pen since daily
feed intake was not reported.
(2): Results of trials 2 and 3 refer to daily gain, results of trial 1 refer to total body weight gain (day 8–43) per bird since daily
weight gain was not reported.
(3): In trial 1, no information was provided on how the feed to gain ratio was calculated.
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in the OPG values were found on any of the observation days between the untreated and the treated
groups and within the uninfected and the infected groups, respectively (Table 8).
No lesions were found for the uninfected groups 7 and 14 days after inoculation (Table 11). Mean
lesion scores of the IT group showed lower values compared to the IUC group only 14 days after
inoculation. Although not signiﬁcant, the frequency of lesion scores in the IUC group decreased for
score 0 from day 7 to 14 after inoculation and increased for the scores 1, 2 and 3. The IT group
showed an inverse picture, increase in score 0 observations and a decrease in scores 1, 2 and 3.
The ﬁnal body weight of the uninfected groups and that of the infected groups were 2,215 g and
2,036 g respectively. Feed to gain ratio showed relations similar to those seen for body weight (Table 12).
3.3.2. Anticoccidial sensitivity tests
Three ASTs were submitted.58 The three tests followed a similar design. Each test was made with
the groups UUC, IUC and IT the latter receiving feed supplemented with 30 mg decoquinate/kg feed
from Deccox® (analysed values 29, 31 and 30 mg decoquinate/kg feed in ASTs 1, 2 and 3,
respectively). Other anticoccidial additives were tested (ﬁve in ASTs 1 and 3, six in AST 2) and the
statistical analysis referred to all groups. The day-old birds (Ross PM3) were randomly allocated to the
groups; group size was 18 chickens (3 replicates with 6 birds).
Supplemented feed was administered from day 13. Birds were artiﬁcially infected on day 15 with
sporulated oocysts from ﬁeld isolates.59 The tests lasted 22 days in total. Endpoints were: body
weight, body weight gain, feed consumption, feed to gain ratio and at the end of the study OPG and
intestinal lesions caused by E. acervulina (and E. maxima in AST 3 and E. tenella in ASTs 1 and 3).
The lesion score scale ranging from 0 to 4 was applied (Johnson and Reid, 1970).
Statistical analysis was performed by one-way ANOVA, group differences were tested by Newman–
Keuls procedure. To approach normal distribution mortality data were transformed by square root and
OPG by natural logarithm. Results are summarised in Table 13.
In all three studies, ﬁnal body weight (body weight gain) and feed to gain ratio of the infected
group was signiﬁcantly improved by the addition of 30 mg decoquinate/kg feed compared to the
untreated group. Signiﬁcantly higher OPG values were found in the infected untreated group compared
to the uninfected group. Decoquinate signiﬁcantly reduced total OPG compared to the IUC group near
to the level of the UUC group. The mean score of intestinal lesions caused by E. acervulina was
signiﬁcantly lower and near to control level when the infected birds received decoquinate. Scores of
Table 13: Summary of anticoccidial sensitivity tests performed with Deccox®
AST
Tr.
group
Feed
Intake
(g/day)
Body
weight
(g)
Weight
Gain (g)
Feed to
gain
Mortality
(n)
Mean lesion scores(1)
OPG 3
106
E.
acervulina
E.
maxima
E.
tenella Total
D13–22 D22 D13–22 D13–22 Total D21 D20–22
1 UUC 100.4 951.0a 559.3a 1.62b 0 0.0b na 0.0c 0c
IUC 83.9 735.4b 343.4b 2.23a 1 (5.6%) 3.0a na 3.3a 902a
IT 98.0 947.9a 555.1a 1.59a 0 0.4b na 1.9b 2.5b
2 UUC 100.8 1017.8a 596.4a 1.52b 0 0.0c na na 0c
IUC 94.9 857.4b 434.0b 1.97a 0 3.4a na na 1102a
IT 104.9 1046.6a 625.0a 1.58b 0 0.7b na na 5b
3 UUC 90.3 1035.6a 610.4a 1.37c 0 0.0b 0.0b 0.0b 0
IUC 76.8 780.7c 353.8c 2.07a 0 3.2a 2.1a 3.3a 646a
IT 79.8 886.5b 456.0b 1.66b 0 0.7b 1.9a 0.2b 27b
Means in columns within a study with different superscript are signiﬁcantly different (p ≤ 0.05). na: not applicable.
(1): 0 = no lesion, 1 = very mild, 2 = mild, 3 = moderate and 4 = severe.
58 AST 1: Technical dossier/Section IV/Annex IV.2.1. AST 2: Annex IV.2.2. AST 3: Annex IV.2.3.
59 AST 1: German ﬁeld isolate (2008); estimated dosage per bird: 251,105 sporulated oocysts (225,550 E. acervulina, 25,555);
AST 2: Poland ﬁeld isolate (2010); estimated dose per bird: 271,100 E. acervulina sporulated oocysts; and AST 3: Belgium
ﬁeld isolate (2010); estimated dose per bird was 273,100 sporulated oocysts (245,000 E. acervulina, 2,500 E. maxima, 25,600
E. tenella).
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lesions caused by E. tenella (ASTs 1 and 3) were also signiﬁcantly reduced by decoquinate. No
signiﬁcant effect was seen in the lesion score related to E. maxima infection.
3.3.3. Conclusions on efﬁcacy
Among the three ﬂoor pen trials submitted, only one (trial 1) provides evidence of the anticoccidial
efﬁcacy of 20 mg decoquinate/kg feed based on endpoints relevant for coccidiostatic efﬁcacy;
however, the study design and reporting showed some weaknesses. Anticoccidial effects by
decoquinate could be seen in trial 2 in reduced lesion scores in the caecum and less pens with blood in
the faeces. The lack of a clear demonstration of anticoccidial efﬁcacy in this trial maybe due to an
insufﬁcient pathogenicity of the Eimeria spp. inoculum. The only positive effect of decoquinate seen in
the third study (trial 3) consists of a decrease in the severity of intestinal lesions with time. In
summary, the anticoccidial efﬁcacy of 20 mg decoquinate/kg complete feed for chickens for fattening
could not be demonstrated by ﬂoor pen trials.
The anticoccidial sensitivity tests demonstrated the efﬁcacy of 30 mg decoquinate/kg feed by an
improvement of all endpoints related to this kind of test.
The three ﬂoor pens studies could not convincingly demonstrate the efﬁcacy of decoquinate
whereas the three anticoccidial sensitivity tests did. Since an assessment of the anticoccidial potential
of an active substance has to be based on the positive outcome of three studies of each study type,
the potential of decoquinate to prevent coccidiosis in chickens for fattening at the lowest applied dose
of 20 mg/kg complete feed cannot be established.
3.4. Post-market monitoring
Field monitoring of Eimeria spp. resistance to decoquinate should be undertaken, preferably during
the latter part of the period of authorisation.
4. Conclusions
Decoquinate from Deccox® is safe for chicken for fattening at the highest proposed concentration
in complete feed of 40 mg/kg. The margin of safety is between 5 and 10.
No practically relevant interactions with other additives or veterinary drugs exist except with
bentonite. Decoquinate does not have antibacterial action.
Decoquinate is not genotoxic and is not carcinogenic. Deccox® is safe for the consumer under the
proposed conditions of use. No withdrawal period is required to ensure consumer safety. No MRLs are
considered necessary.
The inhalation risk for user is considered negligible since inhalation toxicity and exposure are very
low. Deccox® is not an irritant to skin and eyes and has no sensitisation potential.
The PEC/PNEC ratios for terrestrial, aquatic compartment and sediment are below 1, indicating that
decoquinate used in chickens for fattening up to the highest proposed dose, does not pose a risk for
these compartments; as well, no risk is expected neither for secondary poisoning nor for groundwater
contamination.
Due to insufﬁcient evidence, the potential of decoquinate to prevent coccidiosis in chickens for
fattening cannot be established.
Documentation provided to EFSA
1) Deccox® 150G (decoquinate) for chickens for fattening. July 2013. Submitted by Pﬁzer Ltd..
2) Deccox® 150G (decoquinate) for chickens for fattening. June 2014. Supplementary
information. Submitted by Zoetis Belgium SA.
3) Deccox® 150G (decoquinate) for chickens for fattening. April 2015. Supplementary
information. Submitted by Zoetis Belgium SA.
4) Deccox® 150G (decoquinate) for chickens for fattening. September 2016. Supplementary
information. Submitted by Zoetis Belgium SA.
5) Evaluation report of the European Union Reference Laboratory for Feed Additives on the
Methods of Analysis for decoquinate.
6) Comments from Member States.
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EMA European Medicines Agency
EURL European Union Reference Laboratory
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LC50 median lethal concentration
LD50 median lethal dose
LOD limit of detection
log Kow octanol/water partition coefﬁcient
LOQ limit of quantiﬁcation
MIC minimum inhibitory concentrations
MRL maximum residue limit
NOEC no observed effect concentration
NOEL no observed effect level
OECD Organisation for Economic Co-operation and Development
OPG oocysts per gram of excreta
PEC predicted environmental concentration
pKa dissociation constant
PNEC predicted no effect concentration
Deccox® (decoquinate) for chickens for fattening
www.efsa.europa.eu/efsajournal 26 EFSA Journal 2019;17(1):5541
Appendix A – List of references retrieved from the literature search
provided by the applicant
Tolerance
EFSA (European Food Safety Authority), 2003. Opinion of the Scientiﬁc Panel on Additives and
Products or Substances Used in Animal Feed on a request from the Commission on the coccidiostat
Deccox in accordance with article 9G of Council Directive 70524/EEC. EFSA Journal 2003, 17:1-40.
Zhou Y, Yi M, Xu F, et al, 2009. Safety tests of decoquinate solution on the target animal chickens,
Animal Husbandry & Veterinary Medicine, 4, 84-86.
Lee KW, Lillehoij HS, Lee SH, et al, 2012. Effect of dietary antimicrobials on immune status in
broiler chickens. Asian-Australasian Journal of Animal Sciences, 25, 382-92.
Interaction with other drugs
EFSA (European Food Safety Authority), 2010. Scientiﬁc opinion on the safety and efﬁcacy of the
product Cylactin® (Enterococcus faecium) as a feed additive for chickens for fattening. EFSA Journal
2010;8:1661.
EFSA (European Food Safety Authority), 2009. Safety and efﬁcacy of Bonvital (Enterococcus
faecium) as feed additive for chickens for fattening. EFSA Journal 2009;7:1-12.
EFSA (European Food Safety Authority), 2009. Scientiﬁc opinion on the safety and efﬁcacy of
Bacillus subtilis PB6 (Bacillus subtilis) as a feed additive for chickens for fattening, EFSA Journal 2009,7
(9):1314.
Resistance and cross-resistance
EFSA (European Food Safety Authority), 2003. Opinion of the scientiﬁc panel on additives and
products or substances in animal feed on a request from the Commission on the coccidiostat DECCOX
in accordance article 9G of Council Directive 70/524/EEC (Question No. EFSA-Q-2003-044). The EFSA
Journal 2003;17:1-40.
EFSA EMA Committee for Medicinal Products for Veterinary. 2000 Decoquinate Summary Report (2).
Accessed on 6 April 2015.
Cho S, Fossler CP, Diez-Gonzalez F, Wells SJ, Hedberg CW, et al, 2013. Herd-level risk factors
associated with fecal shedding of Shiga toxin-encoding bacteria on dairy farms in Minnesota, USA. The
Canadian Veterinary Journal, 54, 693-7.
Taylor MA, Bartram DJ, 2012. The history of decoquinate in the control of coccidial infections in
ruminants. Journal of Veterinary Pharmacology and Therapeutics, 35, 417-27.
Toxicology
Quintero-de Leonardo J, Rosiles R, Bautista J, et al, 2009. Oral pharmacokinetics and milk residues
of decoquinate in milking cows, Journal of Veterinary Pharmacology & Therapeutics, 32, 403-6.
Li Q, Xie LH, Caridha D, et al, 2014. Long-term prophylaxis and pharmacokinetic evaluation of a
single injection of intramuscular decoquinate in mice infected with plasmodium berghei sporozoites,
American Journal of Tropical Medicine and Hygiene, 91(5 Suppl 1): 85.
EFSA (European Food Safety Authority), 2003. Opinion of the Scientiﬁc Panel on Additives and
Products or Substances Used in Animal Feed on a request from the Commission on the coccidiostat
Deccox in accordance with article 9G of Council Directive 70524/EEC. EFSA Journal 2003; 17:1-40.
Capleton AC, Courage C, Rumsby P, et al, 2006. Prioritizing veterinary medicines according to their
potential indirect human exposure and toxicity proﬁle. Toxicology Letters, 163, 213-23.
Bertelsen U, Dorne J-L CM, Fernandez-Cruz ML, et al, 2008. Risk assessment of coccidiostats after
cross-contamination of feed: Implications for animal and human health, Toxicology Letters (Shannon),
180(Suppl. 1), S61.
Taylor MA, Bartram DJ, 2012. The history of decoquinate in the control of coccidial infections in
ruminants. Journal of Veterinary Pharmacology & Therapeutics, 35, 417-27.
Mercier P, Morel-Sives A, Verdelhan S, et al, 2005. Tolerance of decoquinate in the rabbit,
Proceedings of the 8th World Rabbit Congress (September 7-10, 2004), 597-600.
EFSA (European Food Safety Authority), 2013. Scientiﬁc opinion on the modiﬁcation of
authorisation of Deccox® (decoquinate) as feed additive for chickens for fattening. EFSA Journal
2013;11(10):3370.
Deccox® (decoquinate) for chickens for fattening
www.efsa.europa.eu/efsajournal 27 EFSA Journal 2019;17(1):5541
Dorne JL, Fernandez-Cruz ML, Bertelsen U, et al, 2013. Risk assessment of coccidiostats during
feed cross-contamination: animal and human health aspects. Toxicology & Applied Pharmacology, 270,
196-208.
EMA, 2000. Decoquinate Summary Report (2), European Public MRL Assessment Reports, EMEA/
MRL/722/99.
EFSA (European Food Safety Authority), 2008. Cross-contamination of non-target feedingstuffs by
decoquinate authorised for use as a feed additive. Scientiﬁc opinion of the panel on contaminants in
the food chain. Question No EFSA-Q-2005-220H, EFSA Journal 2008;656:1-26.
Environmental safety of decoquinate
Boxall AB, Fogg LA, Kay P, Blackwell PA, Pemberton EJ, Croxford A, 2003. Prioritisation of veterinary
medicines in the UK environment. Toxicology Letters 142: 207-218.
Capleton AC, Courage C, Rumsby P, Holmes P, Stutt E, Boxall AB, Levy LS, 2006. Prioritising
veterinary medicines according to their potential indirect human exposure and toxicity proﬁle.
Toxicology Letters, 163, 213–223.
Kools SA, Boxall A, Moltmann JF, Bryning G, Koschorreck J, and Knacker T, 2008. A Ranking of
European Veterinary Medicines Based on Environmental Risks. Integrated Environmental Assessment
and Management, 4, 399–408.
Iglesias A, Nebot C, Miranda JM, Vazquez BI, Cepeda A, 2012. Detection and quantitative analysis
of 21 veterinary drugs in river water using high-pressure liquid chromatography coupled to tandem
mass spectrometry. Environmental Science and Pollution Research, 19, 3235–3249.
Iglesias A, Nebot C, Vazquez BI, Miranda JM, Franco Abuın CM, Cepeda A, 2014. Detection of
veterinary drug residues in surface waters collected nearby farming areas in Galicia, North of Spain.
Environmental Science and Pollution Research, 21, 2367–2377.
Shinn AP, Wootten R, Co^te I, Sommerville C, 2003. Efﬁcacy of selected oral chemotherapeutants
against Ichthyophthirius multiﬁliis (Ciliophora: Ophyroglenidae) infecting rainbow trout Oncorhynchus
mykiss. Diseases of Aquatic Organisms, 55, 17–22.
Deccox® (decoquinate) for chickens for fattening
www.efsa.europa.eu/efsajournal 28 EFSA Journal 2019;17(1):5541
Annex A – Executive Summary of the Evaluation Report of the European
Union Reference Laboratory for Feed Additives on the Method(s) of
Analysis for Deccox®
Deccox® is a feed additive currently authorised in chickens for fattening by Commission Regulation
(EC) No 1289/2004 belonging to the group ‘Coccidiostats and other medicinal substances’ listed in
Chapter I of Annex B of Directive 70/524/EEC. In the current application an authorisation of an
existing product under article 10 (2) of the Regulation (EC) No 1831/2003 is requested. Deccox®
consists of 6% decoquinate, 0.6% colloidal silica, 2.85% soya-bean oil on a wheat middlings carrier.
The Deccox® active substance is decoquinate, a quinoline coccidiostat, with a minimum purity of 98%.
Deccox® is a buff-coloured coarse powder formulation to be incorporated in feedingstuffs through
premixtures. The Applicant suggested a concentration of decoquinate in feedingstuffs ranging from
20–40 mg/kg.
For the determination of decoquinate in the feed additive, premixtures and feedingstuffs, the
Applicant submitted the ring-trial validated CEN standard method (EN 16162:2012) based on reversed-
phase high performance liquid chromatography coupled to ﬂuorescence detection (RP-HPLC-FL). The
experimental evidence provided, allows the EURL to recommend for ofﬁcial control this CEN standard
method for the determination of decoquinate in the feed additive, in premixtures and feedingstuffs.
For the determination of decoquinate residues in tissues, the Applicant submitted a single
laboratory validated and further veriﬁed method, based on reversed-phase high-performance liquid
chromatography coupled to a triple quadrupole mass spectrometer in electrospray ionisation mode
(RP-HPLC–MS/MS) using matrix matched standards. The following performance characteristics are
reported: precision (repeatability and/or intermediate precision) ranging from 0.9 to 7.2% and a
recovery rate ranging from 95 to 110%. Based on the performance characteristics presented, the
EURL recommends for ofﬁcial control the RP-HPLC–MS/MS method proposed by the Applicant to
enforce the decoquinate MRLs in the relevant tissues.
Further testing or validation of the methods to be performed through the consortium of National
Reference Laboratories as speciﬁed by Article 10 (Commission Regulation (EC) No 378/2005) is not
considered necessary.
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